Neuroimmunology Drugs Market, By Product Type (Monoclonal Antibodies, Small Molecules, Lymphocytes, Recombinant Protein, and Cytokines), By Indications, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4336
|
Published Date
October 2025
|
Pages
322
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Neuroimmunology Drugs Market size was valued at US$ 25,815.10 Million in 2024, expanding at a CAGR of 9.90% from 2025 to 2032.
Neuroimmunology drugs are primarily used to treat disorders that affect both the nervous and immune systems. These include neurological conditions such as multiple sclerosis (MS), neuromyelitis optica (NMO), and other autoimmune diseases. Many of these neurological disorders are classified as autoimmune conditions, in which the immune system mistakenly targets components of the nervous system—for example, attacking the myelin sheath in MS.
Globally, the market for neuroimmunology therapies is growing rapidly. According to GlobalData, there were nearly 220 neuroimmunology drugs in Phase I–III development across eight major diseases in 8 major pharmaceutical markets as of 2022. The top 20 neuroimmunology products were valued at about US$20.1 billion in 2020, and this is projected to rise to around US$26.6 billion by 2025.
Neuroimmunology Drugs Market- Market Dynamics
Rising Incidence of Neuroimmunological Disorders
The rising prevalence of neuroimmunological disorders is a key factor fueling the growth of the neuroimmunology drug market. As the number of diagnosed cases increases, so does the demand for effective and targeted treatment options. This expanding patient population creates a significant need for innovative therapies, encouraging pharmaceutical companies to invest heavily in research and development (R&D). In turn, this drives the discovery of new drug candidates and advanced treatment approaches.
The surge in diagnoses not only broadens the market but also pushes the industry to diversify its therapeutic offerings to meet the varying needs of patients. Scientists and researchers are increasingly exploring novel mechanisms of action and personalized medicine strategies to improve outcomes. Consequently, the growing incidence of neuroimmunological disorders is directly linked to the expansion of the market, as a larger number of patients require specialized medications to manage their conditions effectively.
The increasing awareness and improved diagnostic capabilities for neuroimmunological disorders are also contributing to market expansion. Advances in neuroimaging, biomarker identification, and genetic testing have made it easier to detect conditions like multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and autoimmune encephalitis at earlier stages. Early diagnosis allows for prompt intervention, which not only improves patient outcomes but also extends the duration of treatment, increasing the overall demand for neuroimmunology drugs. Additionally, healthcare providers and patients are becoming more informed about the benefits of early and continuous treatment, further boosting the adoption of these therapies and reinforcing long-term market growth. Globally, neurological conditions now affect over 3.4 billion people, which is about 43% of the world’s population as of 2021, according to data from the Global Burden of Disease Study.
Neuroimmunology Drugs Market- Segmentation Analysis:
The Global Neuroimmunology Drugs Market is segmented on the basis of Product Type, Indications, and Region.
The neuroimmunology drug market is segmented into six product types: Monoclonal Antibodies, Small Molecules, Lymphocytes, Recombinant Proteins, Cytokines, and Other Product Types. Among these, monoclonal antibodies (mAbs) are anticipated to experience the fastest growth during the forecast period, driven by their increasing use in treating complex neuroimmunological disorders such as Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO). These biologic therapies are designed to modulate or suppress the immune system, targeting specific immune components that drive inflammation. By reducing the inflammatory response and preventing immune-mediated damage to nerve tissues, monoclonal antibodies can help delay disease progression, reduce the frequency of relapses, and preserve neurological function. According to the U.S. National Institutes of Health (NIH), inflammation is a key pathological component in many neurodegenerative and neuroimmunological diseases, and biologics like mAbs are increasingly recognized as pivotal in therapeutic strategies aimed at modifying disease outcomes.
The market is also segmented by nine key indications, including: Multiple Sclerosis (MS), Alzheimer’s Disease, Myasthenia Gravis, Guillain-Barré Syndrome, Parkinson’s Disease, Neuromyelitis Optica Spectrum Disorder (NMOSD), Amyotrophic Lateral Sclerosis (ALS), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), and Other Indications. Among these, the Multiple Sclerosis (MS) segment is expected to grow at the highest Compound Annual Growth Rate (CAGR) during the forecast period. MS is a chronic autoimmune disease in which the body’s immune system mistakenly attacks the myelin sheath—a protective covering around nerve fibers in the central nervous system (CNS). This damage disrupts communication between the brain and the rest of the body, leading to a range of symptoms such as fatigue, vision problems, muscle weakness, and cognitive impairment. The Centers for Disease Control and Prevention (CDC) estimates that nearly 1 million people are living with MS in the United States alone, underscoring the high demand for innovative treatments. Continued advancements in biomedical research have led to the development of new drugs and the repurposing of existing therapies to more effectively target disease mechanisms in MS. These advancements aim to improve patient outcomes, slow disease progression, and expand treatment options.
Neuroimmunology Drugs Market- Geographical Insights
The AsiaPacific region is projected to hold the largest share of the neuroimmunology drugs market during the forecast period. This expansion is fueled by a rising incidence of neuroimmunological disorders such as multiple sclerosis, neuromyelitis optica spectrum disorder (NMOSD), and other autoimmune conditions affecting the nervous system. Enhanced diagnostics, greater awareness, and better access to healthcare are contributing to earlier detection and improved management across countries in this region. Regional governments are responding: many are increasing funding for research, strengthening healthcare infrastructure, and promoting early detection and intervention programs. According to the Global Burden of Disease (GBD) study, in 2021 Asia alone accounted for approximately 1.73 billion people living with neurological diseases, with nearly 479 million new cases diagnosed that year.
In North America, the market is expected to register the highest compound annual growth rate (CAGR). This is largely driven by extensive clinical trial activity, with strong institutional support, robust healthcare systems, and regulatory clarity. Agencies like the U.S. Food and Drug Administration (FDA) and Health Canada help ensure neuroimmunology drugs’ safety and efficacy, which encourages investment. Governments also subsidize or reimburse significant portions of treatment costs through public and private insurance, increasing access to therapy. Financially, direct healthcare spending on brain and neurological disorders globally was estimated at approximately US$1.7 trillion in 2019, with neurological conditions alone accounting for over 50% of that spending.
Neuroimmunology Drugs Market- Competitive Landscape:
The neuroimmunology drugs market is highly competitive, with several major players actively striving to expand their market share. Leading pharmaceutical companies such as Biogen, Hoffmann-La Roche Ltd, T3D Therapeutics, and Novartis AG are at the forefront, investing significantly in research and development to introduce innovative therapies. These companies often maintain diverse drug portfolios targeting a range of neuroimmunological disorders, positioning them as dominant forces within the industry.
In addition to these established firms, numerous smaller biotechnology companies and emerging players are making notable contributions. Many of these smaller entities focus on niche therapeutic areas or pursue novel drug development strategies, fostering innovation and diversifying the market landscape. Key factors fueling market competition include the efficacy and safety of therapies, pricing strategies, regulatory approvals, and market access. Strategic collaborations, partnerships, and acquisitions are common approaches used by companies to enhance their R&D capabilities, expand product pipelines, and reinforce their positions in an evolving and fast-paced market.
Recent Development:
- In June 2023, Roche announced a definitive agreement to acquire Telavant Holdings, Inc., a company jointly owned by Roivant Sciences Ltd. and Pfizer Inc. Under this agreement, Roche will develop, manufacture, and commercialize RVT-3101, Telavant’s lead asset, in the United States and Japan. This acquisition reflects Roche’s commitment to expanding its presence in the neuroimmunology and autoimmune disease space through targeted innovation and strategic growth.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL NEUROIMMUNOLOGY DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Biogen
- Hoffmann-La Roche Ltd
- T3D Therapeutics
- Novartis AG
- Johnson & Johnson
- Celgene Corp
- Merck KGaA
- Eisai Co Ltd
- Sanofi
- Actelion Pharmaceuticals Ltd
- ImmunoBrain Checkpoint
- Lundbeck, Eli Lilly
- AstraZeneca
- UCB SA
- AB Science S.A
- AstronauTx, Genetech Inc
- Inflammasome Therapeutics
- TauRX Therapeutics Ltd
- Others
GLOBAL NEUROIMMUNOLOGY DRUGS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032
- Monoclonal Antibodies
- Small Molecules
- Lymphocytes
- Recombinant Protein
- Cytokines
- Other Product Types
GLOBAL NEUROIMMUNOLOGY DRUGS MARKET, BY INDICATIONS- MARKET ANALYSIS, 2019 - 2032
- Multiple Sclerosis
- Alzheimer\'s Disease
- Myasthenia Gravis
- Guillain-Barre Syndrome
- Parkinson\'s Disease
- Neuromyelitis Optica Spectrum Disorder
- Amyotrophic Lateral Sclerosis
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Other Indications
GLOBAL NEUROIMMUNOLOGY DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Neuroimmunology Drugs Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Neuroimmunology Drugs Market Snippet by Product Type
2.1.2. Neuroimmunology Drugs Market Snippet by Indications
2.1.3. Neuroimmunology Drugs Market Snippet by Country
2.1.4. Neuroimmunology Drugs Market Snippet by Region
2.2. Competitive Insights
3. Neuroimmunology Drugs Key Market Trends
3.1. Neuroimmunology Drugs Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Neuroimmunology Drugs Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Neuroimmunology Drugs Market Opportunities
3.4. Neuroimmunology Drugs Market Future Trends
4. Neuroimmunology Drugs Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Neuroimmunology Drugs Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Neuroimmunology Drugs Market Landscape
6.1. Neuroimmunology Drugs Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Neuroimmunology Drugs Market – By Product Type
7.1. Overview
7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
7.1.2. Monoclonal Antibodies
7.1.3. Small Molecules
7.1.4. Lymphocytes
7.1.5. Recombinant Protein
7.1.6. Cytokines
7.1.7. Other Product Types
8. Neuroimmunology Drugs Market – By Indications
8.1. Overview
8.1.1. Segment Share Analysis, By Indications, 2024 & 2032 (%)
8.1.2. Multiple Sclerosis
8.1.3. Alzheimer\'s Disease
8.1.4. Myasthenia Gravis
8.1.5. Guillain-Barre Syndrome
8.1.6. Parkinson\'s Disease
8.1.7. Neuromyelitis Optica Spectrum Disorder
8.1.8. Amyotrophic Lateral Sclerosis
8.1.9. Chronic Inflammatory Demyelinating Polyradiculoneuropathy
8.1.10. Other Indications
9. Neuroimmunology Drugs Market– By Geography
9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
9.2. North America
9.2.1. Overview
9.2.2. Neuroimmunology Drugs Key Manufacturers in North America
9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.2.5. North America Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.2.6. U.S.
9.2.6.1. Overview
9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.6.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.2.6.4. U.S. Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.2.7. Canada
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.7.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.2.7.4. Canada Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.3. Europe
9.3.1. Overview
9.3.2. Neuroimmunology Drugs Key Manufacturers in Europe
9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.3.5. Europe Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.3.6. Germany
9.3.6.1. Overview
9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.6.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.3.6.4. Germany Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.3.7. UK
9.3.7.1. Overview
9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.7.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.3.7.4. UK Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.3.8. France
9.3.8.1. Overview
9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.8.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.3.8.4. France Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.3.9. Italy
9.3.9.1. Overview
9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.9.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.3.9.4. Italy Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.3.10. Spain
9.3.10.1. Overview
9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.10.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.3.10.4. Spain Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.3.11. The Netherlands
9.3.11.1. Overview
9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.11.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.3.11.4. The Netherlands Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.3.12. Sweden
9.3.12.1. Overview
9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.12.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.3.12.4. Sweden Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.3.13. Russia
9.3.13.1. Overview
9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.13.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.3.13.4. Russia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.3.14. Poland
9.3.14.1. Overview
9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.14.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.3.14.4. Poland Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.3.15. Rest of Europe
9.3.15.1. Overview
9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.3.15.4. Rest of the Europe Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.4. Asia Pacific (APAC)
9.4.1. Overview
9.4.2. Neuroimmunology Drugs Key Manufacturers in Asia Pacific
9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.4.5. APAC Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.4.6. China
9.4.6.1. Overview
9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.6.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.4.6.4. China Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.4.7. India
9.4.7.1. Overview
9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.7.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.4.7.4. India Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.4.8. Japan
9.4.8.1. Overview
9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.8.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.4.8.4. Japan Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.4.9. South Korea
9.4.9.1. Overview
9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.9.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.4.9.4. South Korea Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.4.10. Australia
9.4.10.1. Overview
9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.10.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.4.10.4. Australia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.4.11. Indonesia
9.4.11.1. Overview
9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.11.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.4.11.4. Indonesia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.4.12. Thailand
9.4.12.1. Overview
9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.12.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.4.12.4. Thailand Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.4.13. Philippines
9.4.13.1. Overview
9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.13.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.4.13.4. Philippines Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.4.14. Rest of APAC
9.4.14.1. Overview
9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.14.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.4.14.4. Rest of APAC Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.5. Latin America (LATAM)
9.5.1. Overview
9.5.2. Neuroimmunology Drugs Key Manufacturers in Latin America
9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.5.5. LATAM Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.5.6. Brazil
9.5.6.1. Overview
9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.6.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.5.6.4. Brazil Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.5.7. Mexico
9.5.7.1. Overview
9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.7.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.5.7.4. Mexico Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.5.8. Argentina
9.5.8.1. Overview
9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.8.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.5.8.4. Argentina Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.5.9. Colombia
9.5.9.1. Overview
9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.9.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.5.9.4. Colombia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.5.10. Rest of LATAM
9.5.10.1. Overview
9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.10.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.5.10.4. Rest of LATAM Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.6. Middle East and Africa (MEA)
9.6.1. Overview
9.6.2. Neuroimmunology Drugs Key Manufacturers in Middle East and Africa
9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.6.5. MEA Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.6.6. Saudi Arabia
9.6.6.1. Overview
9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.6.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.6.6.4. Saudi Arabia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.6.7. UAE
9.6.7.1. Overview
9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.7.3. UAE Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.6.7.4. UAE Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.6.8. Israel
9.6.8.1. Overview
9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.8.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.6.8.4. Israel Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.6.9. Turkey
9.6.9.1. Overview
9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.9.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.6.9.4. Turkey Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.6.10. Algeria
9.6.10.1. Overview
9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.10.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.6.10.4. Algeria Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.6.11. Egypt
9.6.11.1. Overview
9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.11.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.6.11.4. Egypt Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
9.6.12. Rest of MEA
9.6.12.1. Overview
9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.12.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
9.6.12.4. Rest of MEA Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
10. Key Vendor Analysis- Neuroimmunology Drugs Industry
10.1. Competitive Benchmarking
10.1.1. Competitive Dashboard
10.1.2. Competitive Positioning
10.2. Company Profiles
10.2.1. Biogen
10.2.2. Hoffmann-La Roche Ltd
10.2.3. T3D Therapeutics
10.2.4. Novartis AG
10.2.5. Johnson & Johnson
10.2.6. Celgene Corp
10.2.7. Merck KGaA
10.2.8. Eisai Co Ltd
10.2.9. Sanofi
10.2.10. Actelion Pharmaceuticals Ltd
10.2.11. ImmunoBrain Checkpoint
10.2.12. Lundbeck, Eli Lilly
10.2.13. AstraZeneca
10.2.14. UCB SA
10.2.15. AB Science S.A
10.2.16. AstronauTx, Genetech Inc
10.2.17. Inflammasome Therapeutics
10.2.18. TauRX Therapeutics Ltd
10.2.19. Others
11. 360 Degree AnalystView
12. Appendix
12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
